{"filing":{"accession_number":"0001193125-26-430974","cik":"0001778016","ticker":"NBP","company_name":"NovaBridge Biosciences","form":"6-K","filing_date":"2026-10-26","report_date":"2026-10-25","primary_document":"6-k_-_giva.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1778016/000119312526430974/6-k_-_giva.htm"},"events":[{"id":37733,"run_id":34775,"accession_number":"0001193125-26-430974","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"This exhibit is a press release announcing updated Phase 1b clinical trial results for givastomig presented at ESMO 2026, including mature follow-up data (18 months median), dose selection (8 mg/kg), and FDA alignment on Phase 3 strategy. While not a traditional earnings release disclosing financial results, it discloses material clinical and regulatory milestones for the company's lead program that would affect investor assessment of the registrant's value and development trajectory. The announcement emphasizes \"registrational-ready\" status and represents a significant inflection point in the program's advancement.","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-10-26","form":"6-K","submitted_at":null,"items":[{"id":42539,"accession_number":"0001193125-26-430974","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing updated Phase 1b clinical trial results for givastomig presented at ESMO 2026, including mature follow-up data (18 months median), dose selection (8 mg/kg), and FDA alignment on Phase 3 strategy. While not a traditional earnings release disclosing financial results, it discloses material clinical and regulatory milestones for the company's lead program that would affect investor assessment of the registrant's value and development trajectory. The announcement emphasizes \"registrational-ready\" status and represents a significant inflection point in the program's advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:04:15.344305+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42539,"accession_number":"0001193125-26-430974","item_number":"EX-99.1","item_title":"nbp-ex99_1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a press release announcing updated Phase 1b clinical trial results for givastomig presented at ESMO 2026, including mature follow-up data (18 months median), dose selection (8 mg/kg), and FDA alignment on Phase 3 strategy. While not a traditional earnings release disclosing financial results, it discloses material clinical and regulatory milestones for the company's lead program that would affect investor assessment of the registrant's value and development trajectory. The announcement emphasizes \"registrational-ready\" status and represents a significant inflection point in the program's advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:04:15.344305+00:00","company_name":"NovaBridge Biosciences","ticker":"NBP","filing_date":"2026-10-26"}]}
